Braveheart Bio (BRVE) news
Recent news
CPBIO renewal of continuing connected transactions, notice of special general meeting
Cancer Prevention & Biotechnology Limited (CPBIO) has announced the renewal of its continuing connected transactions, as disclosed in a recent regulatory filing. The company has also issued a notice of a special general meeting (SGM) to be held on October 30, 2026, for shareholders to consider and…
AInvest Wire · 3d agoCPBIO renewal of continuing connected transactions, notice of special general meeting
AInvest Wire · 3d agoBraveheart Bio, - Q2 net loss attributable to common stockholders was $18.60 mln or $2.51 per share
AInvest Wire · Sep 8, 2026Braveheart Bio, Inc.: Stifel initiates coverage with buy rating; target price $45
Stifel Nicolaus has initiated coverage of Braveheart Bio, Inc. (Nasdaq: BRVE) with a "Buy" rating and a target price of $45 per share. Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious…
AInvest Wire · Aug 31, 2026Braveheart Bio, Inc.: TD Cowen initiates coverage with buy rating
AInvest Wire · Aug 31, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.